Nefopam hydrochloride is an centrally-acting but non-opioid analgesic compound by blocking voltage-gated sodium channel and inhibition of serotonin, dopamine and noradrenaline reuptake.
| Molecular Weight | 289.8 |
| Formula | C17H19NO.HCl |
| CAS Number | 23327-57-3 |
| Form | Solid |
| Solubility (25°C) | DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[2] Bruno Revol, et al. Thirty years of nefopam abuse in France
[3] No authors listed. Nefopam
[5] Y H Tu, et al. Nefopam hydrochloride degradation kinetics in solution
| Related Wnt/beta-catenin Products |
|---|
| Fz7-21
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. |
| FZD7 antagonist 1
FZD7 antagonist 1 (peptide 34) is a dFz7-21 analogue. |
| NLS-StAx-h
NLS-StAx-h is a selective, cell permeable, stapled peptide Wnt signaling inhibitor with an IC50 of 1.4 μM. |
| Zamaporvint
Zamaporvint is an orally active, selective Wnt inhibitor that targets the membrane-bound o-acyltransferase porcupine and inhibits Wnt ligand palmitoylation, secretion and pathway activation. In addition, Zamaporvint displays potent antiproliferative effects in Wnt ligand-dependent colorectal and pancreatic cell lines. It can be used in cancer-related studies. |
| Foxy-5
Foxy-5, a WNT5A agonist and a mimetic peptide of WNT5A, triggers cytoplasmic free calcium signaling without affecting β-catenin activation and inhibits migration and invasion of epithelial cancer cells.Foxy-5 effectively reduces metastatic spread of prostate cancer cells with low WNT5A expression in an in situ mouse model. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
